文献速递前列腺癌

家族史对局限性前列腺癌主要治疗肿瘤学结局的影响:系统综述与荟萃分析

Impact of family history on oncological outcomes in primary therapy for localized prostate cancer patients: a systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-02-15

结果显示阳性家族史与更差的生化复发无生存(汇总HR 0.96,95%CI 0.79-1.17)或癌症特异性生存(汇总HR 1.1,95%CI 0.52-2.35)无关,亚组分析中根治性前列腺切除或放疗患者亦无关联。结论认为家族史不增加局限性前列腺癌患者生化复发或癌症特异性死亡风险。

要点

  • 阳性家族史与局限性前列腺癌患者生化复发无生存无关(汇总HR 0.96,95%CI 0.79-1.17)。
  • 阳性家族史与癌症特异性生存无关(汇总HR 1.1,95%CI 0.52-2.35)。
  • 根治性前列腺切除或放疗亚组中家族史与生化复发无生存亦无关联。

核心结论

  • 家族史不增加局限性前列腺癌患者生化复发或癌症特异性死亡风险。

研究设计与样本

  • 系统综述与荟萃分析,系统检索MEDLINE、Cochrane library和Scopus(2020年5月)。
  • 比较有或无前列腺癌阳性家族史的局限性前列腺癌患者,采用多因素Cox回归分析评估关联。

主要发现

  • 阳性家族史与生化复发无生存无关(汇总HR 0.96;95%CI 0.79-1.17)。
  • 阳性家族史与癌症特异性生存无关(汇总HR 1.1;95%CI 0.52-2.35)。
  • 根治性前列腺切除亚组中阳性家族史与生化复发无生存无关(汇总HR 0.99;95%CI 0.76-1.31)。
  • 放疗亚组中阳性家族史与生化复发无生存无关(汇总HR 0.93;95%CI 0.67-1.30)。

临床怎么用

  • 对于局限性前列腺癌患者,阳性家族史不应被视为生化复发或癌症特异性死亡的高危因素。
  • 在主要治疗决策中,家族史可作为遗传咨询参考,但不作为预后分层依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The influence of family history on oncological outcomes of prostate cancer remains controversial. We conducted a systematic literature review and meta-analysis to investigate the impact of family history of localized prostate cancer on oncological outcomes. METHODS: On May 2020, we systematically searched MEDLINE, the Cochrane library, and Scopus for studies that compared patients who had localized prostate cancer with or without a positive family history of prostate cancer. Our aim was to evaluate the association of family history with biochemical recurrence-free survival, cancer-specific survival, and overall survival by means of a multivariate Cox regression analysis. RESULTS: Eleven studies with 39,716 patients were included in the systematic review, and eight studies with 33,027 patients for the meta-analysis. A positive family history was not associated with worse biochemical recurrence-free survival (pooled HR: 0.96; 95% CI: 0.79-1.17) or cancer-specific survival (pooled HR: 1.1; 95% CI: 0.52-2.35). Subgroup analyses showed no association between positive family history and poor biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy (pooled HR: 0.99; 95% CI: 0.76-1.31) or radiation therapy (pooled HR: 0.93; 95% CI: 0.67-1.30). CONCLUSIONS: This meta-analysis indicated that family history of prostate cancer does not increase the risk of biochemical recurrence or cancer-specific mortality in localized prostate cancer patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Urabe F, Kimura S, Yamamoto S, et al. Impact of family history on oncological outcomes in primary therapy for localized prostate cancer patients: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021. PMID: 33589769. doi:10.1038/s41391-021-00329-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。